Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease

Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease

Abstract Background Although the dopamine precursor L-3, 4-dihydroxyphenylalanine ( l -dopa) remains the gold standard pharmacological therapy for patients with Parkinson’s disease (PD), long-term treatment with this drug has been known to result in several adverse effects, including l -dopa-induced...

Full description

Bibliographic Details
Main Authors: Sora Ahn, Taek-Jin Song, Seong-Uk Park, Songhee Jeon, Jongpil Kim, Joo-Young Oh, Jaehwan Jang, Sanhwa Hong, Min-A Song, Hye-Seoung Shin, Young-Rim Jung, Hi-Joon Park
Format: Article
Language:English
Published: BMC 2017-04-01
Series:BMC Complementary and Alternative Medicine
Subjects:
KD5040
L-dopa combination treatment
Parkinson’s disease
L-dopa-induced dyskinesia
Synergic effect
Enkephalin
Online Access:http://link.springer.com/article/10.1186/s12906-017-1731-2

Internet

http://link.springer.com/article/10.1186/s12906-017-1731-2

Similar Items